Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Nasmed Ozelglik Hizmetleri Ticaret AS EBITDA Margin %?
Nasmed Ozelglik Hizmetleri Ticaret ASIST:EGEPO -2.45%73 EBITDA Margin % is 14.75% as of Dec. 2025, which is 26% below its 10-year median of 19.89. GuruFocus rates IST:EGEPO with a GF Score™ of 73/100 and a GF Value™ of ₺8.41 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Nasmed Ozelglik Hizmetleri Ticaret AS ranks better than 64.86% on this metric.
Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nasmed Ozelglik Hizmetleri Ticaret AS EBITDA Margin % Related Terms
Nasmed Ozelglik Hizmetleri Ticaret AS EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nasmed Ozelglik Hizmetleri Ticaret AS EBITDA Margin % Chart
IST:EGEPO vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Nasmed Ozelglik Hizmetleri Ticaret AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasmed Ozelglik Hizmetleri Ticaret AS EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nasmed Ozelglik Hizmetleri Ticaret AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nasmed Ozelglik Hizmetleri Ticaret AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO) has a EBITDA Margin % of 14.75% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nasmed Ozelglik Hizmetleri Ticaret AS and its competitors. This is 26% below median its historical median of 19.89. According to the industry distribution chart, Nasmed Ozelglik Hizmetleri Ticaret AS ranks #234 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 35.1%.
Is Nasmed Ozelglik Hizmetleri Ticaret AS's EBITDA Margin % too high?
Nasmed Ozelglik Hizmetleri Ticaret AS's current EBITDA Margin % of 14.75% is 26% below median its 10-year median of 19.89. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Nasmed Ozelglik Hizmetleri Ticaret AS's value of 14.75% is 44.1% above this industry median. Based on the distribution chart, Nasmed Ozelglik Hizmetleri Ticaret AS ranks #234 out of 666 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Nasmed Ozelglik Hizmetleri Ticaret AS has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nasmed Ozelglik Hizmetleri Ticaret AS's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nasmed Ozelglik Hizmetleri Ticaret AS ranks #234 out of 666 companies for EBITDA Margin %. This puts Nasmed Ozelglik Hizmetleri Ticaret AS in the upper half of its industry. The industry median EBITDA Margin % is 10.24. Nasmed Ozelglik Hizmetleri Ticaret AS's value of 14.75% is 44.1% above this benchmark. While the company's 10-year median is 19.89 vs. the industry median of 10.24, Nasmed Ozelglik Hizmetleri Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nasmed Ozelglik Hizmetleri Ticaret AS's current EBITDA Margin % of 14.75% is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nasmed Ozelglik Hizmetleri Ticaret AS and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nasmed Ozelglik Hizmetleri Ticaret AS's current EBITDA Margin % is 14.75%, which is 26% below median its own 10-year median of 19.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasmed Ozelglik Hizmetleri Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺8.41, compared to a current price of ₺18.28 — trading 117.4% above its estimated fair value. The current EBITDA Margin % is 14.75%, which is 26% below median its 10-year median of 19.89 and 44.1% above the Healthcare Providers & Services industry median of 10.24. Nasmed Ozelglik Hizmetleri Ticaret AS's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO), the current EBITDA Margin % is 14.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO) Overvalued in 2026?
Based on GuruFocus' analysis, Nasmed Ozelglik Hizmetleri Ticaret AS stock appears to be overvalued.
The current stock price of ₺18.28 is trading 117.4% above its estimated GF Value™ of ₺8.41.
GuruFocus considers Nasmed Ozelglik Hizmetleri Ticaret AS to be Significantly Overvalued.
Key valuation signals for IST:EGEPO:
EBITDA Margin %: 14.75% (26% below median its 10-year median of 19.89)
GF Value™: ₺8.41 vs. price of ₺18.28 (117.4% above fair value)
Industry Position: 44.1% above the Healthcare Providers & Services median (#234 of 666)
No single metric tells the full story. See the IST:EGEPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nasmed Ozelglik Hizmetleri Ticaret AS Business Description
Nasmed Ozel Saglik Hizmetleri Ticaret AS provides quality healthcare services. It arranges consultations, travel planning, accommodation, translation, and other relevant services for its patients 24/7.
73GF Score
Get the complete analysis for IST:EGEPO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:EGEPO has been successfully added to your 
